Spots Global Cancer Trial Database for Tislelizumab as Cross-line Treatment for Advanced NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tislelizumab as Cross-line Treatment for Advanced NSCLC
Official Title: Tislelizumab Combined With Docetaxel for Cross-line Treatment of First-line Resistant Advanced NSCLC，a Phase II Clinical Study
Study ID: NCT05192681
Conditions
Interventions
Study Description
Brief Summary: This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and continuing Tislelizumab in combination with docetaxel. The primary study endpoint of this study is measured by progression-free survival (PFS). 1. Tislelizumab: The recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle. 2. Docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle. 3. Treatment cycle: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fujian cancer hospital, Fuzhou, Fujian, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
